Respiratory syncytial virus vaccine
A respiratory syncytial virus vaccine, or RSV vaccine, is a vaccine that protects against respiratory syncytial virus. RSV affects an estimated 64 million people and causes 160,000 deaths worldwide each year.
| Vaccine description | |
|---|---|
| Target | RSVPreF3 antigen |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Arexvy, Abrysvo |
| Other names | GSK3844766A, respiratory syncytial virus vaccine, adjuvanted |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
The RSV vaccines Arexvy (GSK), and Abrysvo (Pfizer), are approved for medical use in the United States. Arexvy is approved for medical use in the European Union and in Canada for adults aged 60 or older.
Research to develop an RSV vaccine continued for decades; a 2013 study led to the approved vaccines. Work on RSV vaccines also supported the rapid development of COVID-19 vaccines.
Abrysvo is also approved in the US for use in pregnant women at 32 through 36 weeks gestational age to protect infants from birth through six months of age. Abrysvo is approved for use in pregnant women at 24 through 36 weeks and older adults in the European Union. and between 28 through 36 weeks and older adults in the UK.
Infant-specific issues include the immature infant immune system and the presence of maternal antibodies, which make infantile immunization difficult.